Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells

• Published in: Biochimica et biophysica acta. General subjects Vol. 1861; no. 11; pp. 2980 - 2992
• Main Authors: Kozar, Ines, Cesi, Giulia, Margue, Christiane, Philippidou, Demetra, Kreis, Stephanie
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.11.2017
• Subjects: biomarkers; BRAF inhibitors; Cell Line, Tumor; Drug resistance; Drug Resistance, Neoplasm - genetics; drugs; Gene Expression Profiling; gene expression regulation; Gene Expression Regulation, Neoplastic - drug effects; genes; Humans; long term effects; Melanoma; Melanoma - drug therapy; Melanoma - genetics; Melanoma - pathology; metastasis; Microarray Analysis; microRNA; MicroRNAs - drug effects; MicroRNAs - genetics; miRNA; patients; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Proto-Oncogene Proteins B-raf - antagonists & inhibitors; quantitative polymerase chain reaction; reverse transcriptase polymerase chain reaction; skin neoplasms; Skin Neoplasms - drug therapy; Skin Neoplasms - genetics; Skin Neoplasms - pathology; synthetic biology; Targeted therapy; therapeutics; transcriptome; Transcriptome - drug effects; PCSK2; Targeted therapy; BRAF inhibitors; WFDC1; HIF-1α; Drug resistance; CYR61; NRAS; SESN2; CCL2; CTLA4; miRNA; CHAC1; EDIL3; PC2; CE; Melanoma; ASNS; GP; BRAF; MITF; MAPK; EMT; PCA; DCT; AXL; DOK5; NF1; XP; HRE

Melanoma is an aggressive skin cancer with increasing incidence worldwide. The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF-mutant tumours contributed profoundly to an improved overall survival of patients with metastatic melanoma. Despite these promising resul...